Dipeptidyl peptidase IV inhibition alters the hemodynamic response to angiotensin-converting enzyme inhibition in humans with the metabolic syndrome.
Jackson
Edwin K
EK
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D004359:Drug Therapy, Combination; D004656:Enalapril / Q000627:therapeutic use*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D024821:Metabolic Syndrome / Q000188:drug therapy* / Q000503:physiopathology; D008954:Models, Biological; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000627:therapeutic use*
D000806:Angiotensin-Converting Enzyme Inhibitors; D011719:Pyrazines; D014230:Triazoles; D004656:Enalapril; D018819:Dipeptidyl Peptidase 4; D007703:Peptidyl-Dipeptidase A; D000068900:Sitagliptin Phosphate